109 results about "He Antibody" patented technology

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes.

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes.

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

The present invention is directed to improved therapeutics against receptors within the EGFR / ErbB / HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

The present invention provides a novel antibody-RNase conjugate which is a single chain protein, providing both the specificity of its antibody portion and the RNase activity of its RNase portion, resulting in an antigen specific effectiveness against cells when applied in vivo or in vitro, wherein the RNase portion is effectively cytotoxic in at least a fraction of cells presenting the antigen, e.g. after internalization by endocytosis. In detail, the present invention provides scAb-RNase conjugate having the principal structure of scFvFc-RNase. This structure could also be shown to allow the effective production of antigen-specific and cytotoxic conjugate protein in cell culture, the conjugate having a high activity with respect to antigen specificity and cyto toxicity.

This document provides methods and materials related to detecting allergens (e.g., food allergens) and / or specific antibodies in individualized consumers that are specific to an allergen (e.g., a food allergen). For example, methods and materials for assessing a food sample for the presence or absence of food allergens are provided. In addition, methods and materials for assessing if a particular human will react with those exact food allergens given his / her antibody profile are provided.

The invention provides an H7 subtype avian influenza virus monoclonal antibody of and kit, and obtains hybridoma cell strain that secretes H7 subtype avian influenza virus monoclonal antibody, wherein the accession number of the hybridoma cell strain is CGMCC NO. 7308, and the obtained H7 subtype avian influenza virus monoclonal antibody is provided with advantages like high sensitivity, strong singularity and high bioactivity etc., which can be used to identify if the virus to be tested is H7 subtype avian influenza virus, and if the sample to be tested is infected by H7 subtype avian influenza virus, and if the serum to be tested contains H7 subtype avian influenza virus. The monoclonal antibody above also could be used to prepare immunological diagnostic reagent of H7 subtype avian influenza virus or its antibody, such as Enzyme-linked diagnostic reagent and colloidal gold immunoassay kit or the like, and also could detect if the poultry feces, the oral and nasal secreta or the stool contains H7 subtype avian influenza virus and if the poultry serum contains H7 subtype avian influenza virus antibody.

In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains. The present invention addresses this issue by disclosing synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine residues and differences between mono-, di-, and tri-methylation. The methylated peptide is useful as an antigen and a binding partner for identifying compounds that interact with the peptide and the methylated tau protein, including antibodies that can distinguish non-diseased brain from that affected by Alzheimer's disease. The resulting antibodies are useful diagnostically and therapeutically. The compounds that specifically bind to methylated tau proteins are useful for eliminating abnormally methylated tau.

The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.

The invention relates to a kit for dual detection of viruses by nucleic acid and antibodies and preparation method thereof. According to the invention, an RPA primer and a probe which specifically aimat H1N1 detection are obtained by analyzing an H1N1 sequence, and the RPA primer and the probe are prepared into a corresponding detection test strip. At the same time, monoclonal antibodies which have good effects are screened and obtained aiming at an H1N1 conserved region. An H1N1 influenza virus fluorescence quantum dot rapid detection test paper is prepared from a monoclonal antibody labeledquantum dot and other antibody labeled nitrocellulose membranes. The two detection methods are combined for use, so that the detection accuracy can be further improved, the cost is low, and the kit and method is suitable for large-scale popularization.

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

The invention provides a CCP peptide segment, an antigen containing the CCP peptide segment, a reagent, a kit and an application. The CCP peptide has a structure shown as NH2-S3-S1-X-S2-S4-COOH, X isa citrulline-containing epitope region, S1 and S2 are flanking regions of the citrulline-containing epitope region, at most one of S1 and S2 is a charged amino acid residue, and S3 and S4 are amino acid residue regions connected to form a loop so as to form an amino acid residue region of the CCP peptide segment. The flanking regions of the CCP peptide segment are composed of amino acids with at most one amino acid serving as a charged amino acid, so that the intermolecular acting force can be reduced or the formation of an antigenic epitope can be avoided, the probability is reduced that thecitrulline antibody recognizes amino acid residues outside a key region to form an antigenic epitope and is recognized by other antibodies, thus the probability is reduced that the anti-cyclic citrulline peptide antibody is detected in the serum of non-RA patients, and the clinical detection specificity of the anti-cyclic citrulline peptide antibody in the diagnosis of RA diseases is improved.

The invention discloses an expression of cymbidium mosaic virus (Cymbidium Mosaic Virus, CymMV) coat protein gene and a preparation method for antibody of cymbidium mosaic virus coat protein gene. A prokaryotic expression system is used for expressing the coat protein of the cymbidium mosaic virus, and the cymbidium mosaic virus coat protein gene immune rabbit, the BALB / C mouse are used for preparing the polyclonal anti-serum; and the hybridoma technique is used for preparing the monoclonal antibody, and the prepared antibody is used for establishing the immune capture RT-PCR and ELISA method for detecting the high specificity, sensitivity and accuracy of CymMV. The invention provides technical support for the diagnosis of the virus, disease-resistance breeding and cultivation of virus-free seedlings. The expression of cymbidium mosaic virus coat protein gene and the preparation method for its antibody provided by the invention provides material base and technical support for rapid detection and diagnosis of the cymbidium mosaic virus, typing and the study on molecular biology, and lays the foundations for prevention and treatment of cymbidium mosaic virus disease.

The invention discloses a Riemerella anatipestifer OmpA / MotB truncated recombinant protein, its antibody and a preparation method and an application thereof. The recombinant protein has immunoreactivity similar to natural OmpA / MotB protein, can bind to RA antibody specifically, will not generate cross reactions with Salmonella anatum positive serum, duck colibacilosis positive serum, duck swollen head septicemia virus positive serum, avian influenza virus (H5) positive serum, duck plague virus positive serum, duck hepatitis virus positive serum and the like, and can be used as a detection antigen for detecting whole bacteria antibody. As the recombinant protein is not whole bacteria, there is no risk of spreading bacteria when the recombinant protein is applied to detection. In addition, the preparation method of the recombinant protein is simple, is suitable for large-scale industrial production, can realize standardization of products and is beneficial to result comparison between different laboratories.

The invention relates to three-kind of membrane protein of the white spot syndrome virus: VP68,VP281,VP466 having the infective function. Their differential polyclonal antibodies have the ability of resisting the white spot syndrome virus. The invention also deals with the apply of the differential polyclonal antibody of three kinds of membrane protein of the white spot syndrome virus: VP68,VP281,VP466and the producing method of the said membrane protein VP68,VP281,VP466 and their differential polyclonal antibody.

A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO). Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.

The invention refers to a zinc protein and the antibody, relative to human hematogenic system growth. The ZNF 268 protein is a typical krIIppel-type C2H2 zinc protein; the preparation mainly structures ZNF268 expression carrier, transfers into host cells to express and separate to purify ZNF268 protein; the protein can diagnose and treat the disease because of protein abnormity. The antibody of ZNF268 protein can exceptionally combine with ZNF268 protein. The antibody preparation; mix the ZNF268 protein and assist agent to immunize animal, then separate the immune antimal blood to purify the antibody; the antibody; the antibody can diagnose, treat or prevent the disease relative to the protein abnormity of ZNF268 protein.

The invention provides a luminescence immune detection method based on a recombinant antigen carrying a His tag. His-tag-carried recombinant protein serving as a known antigen, His antibody coating resistant luminescent microspheres, biotin labeled second antibodies and streptavidin labeled light sensing microspheres jointly form a detection reagent. According to the method, the recombinant protein carrying the His tag is taken as the known antigen, the method has the most important characteristic that the known antigen is arranged in liquid-phase three-dimensional space, which is essentially different from an immobilized antigen in the prior art. Due to the change, the technical problems caused by the immobilization process in a traditional antibody detection method are effectively solved. Besides, a homogeneous-phase luminescence immunoassay system based on active oxygen energy transmission is adopted and has higher analysis sensitivity and precision.

Production of CD20 chimeric antibody and its use are disclosed. The process is based on preparation of anti-human CD20 single-cloning antibody hybridoma cell 1-28 and its antibody gene. It has cognitive epitope characteristic and mediated killer target cell functions.

The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.

The invention relates to a miniature blood detector for rapidly detecting an acute myocardial infarction marker, and a detection method thereof. The miniature blood detector comprises a blood sample inlet (1), a blood separator (2), a serum sample outlet (3), an immunoadsorption reactor (4), a pH-sensitive field effect transistor (5) and a micro-current detection circuit (6); the blood sample is injected from the sample inlet (1), and flows through a blood separation membrane (9), serum enters the immunoadsorption reactor (4), an acute myocardial infarction marker antigen in the serum specifically binds to its antibody, and is cross-linked with an enzyme in order to cause the change of the pH value of a reaction solution in order to change the current signal of the pH-sensitive field effect transistor (5), the current signal is output by the micro-current detection circuit (6), and the concentration of the measured marker is displayed. The concentration of the acute myocardial infarction marker is detected by using whole blood as a biological sample, combining a membrane separation technology with a micro biosensor element, integrating the blood separation membrane with the micropH-sensitive field effect transistor, performing an electronic enzyme-linked immunosorbent reaction and adopting current response as an output in order to quickly and easily achieve clinical detectionof acute myocardial infarction.

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies.

A solid-phase immunoassay for 6-keto-Prostaglandin F1α, the stable hydrolysis product of prostacyclin (Prostaglandin I2) is disclosed. Prostacyclin, a potent vasodilator with anti-platelet and anti-proliferative properties is an effective treatment for primary pulmonary hypertension and pulmonary arterial hypertension associated with scleroderma and scleroderma-like syndrome. Levels of 6-keto-Prostaglandin F1α can be directly correlated with levels of prostacyclin. Therefore, 6-keto-Prostaglandin F1α has become the indicator of choice to measure prostacyclin levels. The single step immunoassay for 6-keto-Prostaglandin F1α uses the bioluminescent protein, aequorin as a label. Analyte-label conjugates were constructed by linking the carboxyl group of 6-keto-Prostaglandin F1α and lysine residues of aequorin by chemical conjugation methods. The binding properties of 6-keto-Prostaglandin F1α towards its antibody and the bioluminescent properties of aequorin are retained in the conjugate. The concentration of 6-keto-Prostaglandin F1α after extraction from plasma shows good correlation with the concentration of 6-keto-Prostaglandin F1α obtained without prior extraction of the same plasma sample. The assay allows the measurement of 6-keto-Prostaglandin F1α directly in plasma without any pre-treatment of the samples, which results in a much simpler method with a faster assay time.

The invention discloses a method to quickly detect alpha-fetoprotein, comprising: applying single-wall carbon nanotube alpha-fetoprotein antibody dispersion to a paper base; measuring resistance of apaper-based carbon nanotube sensor according to resistance changes of the paper-based sensor before and after antibody and antigen combination by making use of the characteristic that alpha-fetoprotein can specifically bind with its antibody; recording changes in the resistance of the sensor for certain time so as to measure the content of a target antigen so that quick detection is achieved. Themethod herein has the advantages of good simplicity, high speed, low time consumption, good convenience and the like, and is especially suitable for early screening of cancers.

A process for treating a patient with leukemia or an aplastic anemia having cells with inclusions that stain with anti-E. canis antibodies or antibodies to other Ehrlichia or Anaplasma is disclosed. That process comprises administering to the patient (i) an antibacterial amount of a rifamycin, (ii) an antibacterial amount of a quinolone, or a mixture of (i) and (ii).